The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of ...
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...
Last week, the U.S. Food and Drug Administration (FDA) approved the use of Darzalex Faspro (daratumumab and ...
MedPage Today on MSN
Mutant Wolves and Cancer; Lung Cancer in Never-Smokers; Saving Female Sexual Anatomy
News, features, and commentary about cancer-related issues ...
The biopharmaceutical company received expedited development designation from American regulators for its trispecific ...
Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple ...
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...
The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...
The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.
DARZALEX FASPRO ® U.S. Prescribing Information. 2 Johnson & Johnson Innovative Medicine. DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet ...
Darzalex Faspro is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase.
Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while underscoring the need for strategies that optimize long-term tolerability, immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results